EMEA-001943-PIP02-20-M01
Key facts
Invented name |
Ultomiris
|
Active substance |
ravulizumab
|
Therapeutic area |
|
Decision number |
P/0189/2022
|
PIP number |
EMEA-001943-PIP02-20-M01
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of patients with haematopoietic stem cell transplant associated thrombotic microangiopathy
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Alexion Europe SAS
E-mail: pip.enquiries.eu@alexion.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|